Heteromeric dopamine receptor signaling complexes: Emerging neurobiology and disease relevance

Neuropsychopharmacology

Volumn 39, Issue 1, 2014, Pages 156-168

  Perreault, Melissa L ^a,b   Hasbi, Ahmed ^a,b   O'dowd, Brian F ^a,b   George, Susan R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

dopamine receptor heteromers; G protein coupled receptor; heterooligomerization; neuropsychiatric disorders; receptor complexes; receptor dimerization

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H3 RECEPTOR; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ADENOSINE RECEPTOR; DOPAMINE RECEPTOR;

ADDICTION; ALLOSTERISM; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; NEUROBIOLOGY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; HUMAN; MENTAL DISORDERS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN MULTIMERIZATION;

ANIMALS; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; PROTEIN MULTIMERIZATION; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 84890454393     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.148     Document Type: Review

References (129)

1. Albizu L, Holloway T, Gonzá lez-Maeso J, Sealfon SC (2011). Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 61: 770-777
2. Altink ME, Rommelse NN, Slaats-Willemse DI, Vá squez AA, Franke B, Buschgens CJ et al. (2012). The dopamine receptor D4 7-repeat allele influences neurocognitive functioning, but this effect is moderated by age and ADHD status: An exploratory study. World J Biol Psychiatry 13: 293-305
3. Andersen MB, Fuxe K, Werge T, Gerlach J (2002). The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav Pharmacol 13: 639-644
4. Anderson SM, Famous KR, Sadri-Vakili G, Kumaresan V, Schmidt HD, Bass CE et al. (2008). CaMKII: A biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nat Neurosci 11: 344-353
5. Azdad K, Gall D, Woods AS, Ledent C, Ferré S, Schiffmann SN (2009). Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34: 972-986
6. Bahi A, Boyer F, Chandrasekar V, Dreyer JL (2008). Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats. Psychopharmacology (Berl) 199: 169-182
7. Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH et al. (2011). Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur J Med Chem 46: 799-803
8. Balboni G, Salvadori S, Trapella C, Knapp BI, Bidlack JM, Lazarus LH et al. (2010). Evolution of the bifunctional lead m agonist/ d antagonist containing the Dmt-Tic opioid pharmacophore. ACS Chem Neurosci 1: 155-164
9. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U (2007). Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19: 2304-2316
10. Beaulieu JM, Gainetdinov RR (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217
11. Beaulieu JM, Gainetdinov RR, Caron MG (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28: 166-172
12. Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E et al. (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28: 5671-5685
13. Boison D, Singer P, Shen HY, Feldon J, Yee BK (2012). Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy. Neuropharmacology 62: 1527-1543
14. Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Marcellino D, Ciruela F, Agnati LF et al. (2010). Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers. Biochem Biophys Res Commun 401: 605-610
15. Borroto-Escuela DO, Van Craenenbroeck K, Romero-Fernandez W, Guidolin D, Woods AS, Rivera A et al. (2011). Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions. Biochem Biophys Res Commun 404: 928-934
16. Cabello N, Gandia J, Bertarelli DC, Watanabe M, Lluís C, Franco R et al. (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 109: 1497-1507
17. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR et al. (2003). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278: 46741-46749
18. Ciruela F, Burgueño J, Casadó V, Canals M, Marcellino D, Goldberg SR et al. (2004). Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem 76: 5354-5363
19. Coyle JT (2012). NMDA receptor and schizophrenia: A brief history. Schizophr Bull 38: 920-926
20. Dziedzicka-Wasylewska M, Faron-Gó recka A, Andrecka J, Polit A, Kuś mider M, Wasylewski Z (2006). Fluorescence studies reveal heterodimerization of dopamine D1 and D2 receptors in the plasma membrane. Biochemistry 45: 8751-8759
21. Dziedzicka-Wasylewska M, Faron-Gó recka A, Gó recki A, Kuś mider M (2008). Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization-A working hypothesis. Pharmacol Rep 60: 581-587
22. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131-137
23. Faraone SV, Biederman J (1998). Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 44: 951-958
24. Faron-Gó recka A, Gó recki A, Kuś mider M, Wasylewski Z, Dziedzicka-Wasylewska M (2008). The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine. Eur Neuropsychopharmacol 18: 682-691
25. Ferrada C, Ferré S, Casadó V, Corté s A, Justinova Z, Barnes C et al. (2008). Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 55: 190-197
26. Ferrada C, Moreno E, Casadó V, Bongers G, Corté s A, Mallol J et al. (2009). Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 157: 64-75
27. Ferré S, Agnati LF, Ciruela F, Lluís C, Woods AS, Fuxe K et al. (2007). Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res Rev 55: 55-67
28. Ferré S, Lluís C, Lanciego JL, Franco R (2010). Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: The dopamine D(1)-D(3) receptor heteromer. CNS Neurol Disord Drug Targets 9: 596-600
29. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008). Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74: 59-69
30. Fiorentini C, Gardoni F, Spano P, Di Luca M, Missale C (2003). Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-Aspartate receptors. J Biol Chem 278: 20196-20202
31. Franco R, Ferré S, Agnati L, Torvinen M, Giné s S, Hillion J et al. (2000). Evidence for adenosine/dopamine receptor interactions: Indications for heterodimerization. Neuropsychopharmacology 23: S50-S59
32. Franco R, Lluís C, Canela EI, Mallol J, Agnati L, Casadó V et al. (2007). Receptorreceptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm 114: 93-104
33. Freyberg Z, Ferrando SJ, Javitch JA (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167: 388-396
34. Fuxe K, Ferré S, Canals M, Torvinen M, Terasmaa A, Marcellino D et al. (2005). Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci 26: 209-220
35. Fuxe K, Marcellino D, Leo G, Agnati LF (2010). Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr Opin Pharmacol 10: 14-22
36. Fuxe K, Marcellino D, Rivera A, Díaz-Cabiale Z, Filip M, Gago B et al. (2008). Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 58: 415-452
37. Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B et al. (2001). Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 20: 2152-2159
38. George SR, O'Dowd BF (2007). A novel dopamine receptor signaling unit in brain: Heterooligomers of D1 and D2 dopamine receptors. ScientificWorldJournal 7: 58-63
39. George SR, O'Dowd BF, Lee SP (2002). G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 1: 808-820
40. Giné s S, Hillion J, Torvinen M, Le Crom S, Casadó V, Canela EI et al. (2000). Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97: 8606-8611
41. Gonzá lez S, Rangel-Barajas C, Peper M, Lorenzo R, Moreno E, Ciruela F et al. (2012). Dopamine D4 receptor, but not the ADHD-Associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol Psychiatry 17: 650-662
42. Gorinski N, Kowalsman N, Renner U, Wirth A, Reinartz MT, Seifert R et al. (2012). Computational and experimental analysis of the transmembrane domain 4/5 dimerization interface of the serotonin 5-HT(1A) receptor. Mol Pharmacol 82: 448-463
43. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW (2007). Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-Administration and relapse. Nat Neurosci 10: 1029-1037
44. Graham DL, Krishnan V, Larson EB, Graham A, Edwards S, Bachtell RK et al. (2009). Tropomyosin-related kinase B in the mesolimbic dopamine system: Region-specific effects on cocaine reward. Biol Psychiatry 65: 696-701
45. Guixà-Gonzá lez R, Bruno A, Marti-Solano M, Selent J (2012) Crosstalk within GPCR heteromers in schizophrenia and Parkinson's disease: Physical or just functional? Curr Med Chem 19: 1119-1134
46. Guo W, Shi L, Javitch JA (2003). The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem 278: 4385-4388
47. Gurevich VV, Gurevich EV (2008). How and why do GPCRs dimerize? Trends Pharmacol Sci 29: 234-240
48. Hague C, Uberti MA, Chen Z, Hall RA, Minneman KP (2004). Cell surface expression of alpha1D-Adrenergic receptors is controlled by heterodimerization with alpha1B-Adrenergic receptors. J Biol Chem 279: 15541-15549
49. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF et al. (2009). Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 106: 21377-21382
50. Hasbi A, O'Dowd BF, George SR (2010). Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. Curr Opin Pharmacol 10: 93-99
51. Hillion J, Canals M, Torvinen M, Casadó V, Scott R, Terasmaa A et al. (2002). Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277: 18091-18097
52. Huang J, Chen S, Zhang JJ, Huang XY (2013). Crystal structure of oligomeric beta1-Adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol 20: 419-425
53. Jackson SN, Wang HY, Yergey A, Woods AS (2006). Phosphate stabilization of intermolecular interactions. J Proteome Res 5: 122-126
54. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-Term administration of phencyclidine. Science 277: 953-955
55. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M et al. (1998). GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396: 674-679
56. Jordan BA, Devi LA (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700
57. Kamiya T, Saitoh O, Yoshioka K, Nakata H (2003). Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 306: 544-549
58. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE et al. (2010). Signaling pathways in schizophrenia: Emerging targets and therapeutic strategies. Trends Pharmacol Sci 31: 381-390
59. Karpa KD, Lin R, Kabbani N, Levenson R (2000). The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol Pharmacol 58: 677-683
60. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P et al. (1998). GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396: 683-768
61. Kebir O, Joober R (2011). Neuropsychological endophenotypes in attention-deficit/ hyperactivity disorder: A review of genetic association studies. Eur Arch Psychiatry Clin Neurosci 261: 583-594
62. Kong MM, Fan T, Varghese G, O'Dowd BF, George SR (2006). Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homooligomer. Mol Pharmacol 70: 78-89
63. Koo JW, Mazei-Robison MS, Chaudhury D, Juarez B, LaPlant Q, Ferguson D et al. (2012). BDNF is a negative modulator of morphine action. Science 338: 124-128
64. Kruse MS, Premont J, Krebs MO, Jay TM (2009). Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. Eur Neuropsychopharmacol 19: 296-304
65. Kühhorn J, Götz A, Hübner H, Thompson D, Whistler J, Gmeiner P (2011). Development of a bivalent dopamine D2 receptor agonist. J Med Chem 54: 7911-7919
66. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y et al. (2002). Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111: 219-230
67. Lee SP, O'Dowd BF, Rajaram RD, Nguyen T, George SR (2003). D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42: 11023-11031
68. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lanca AJ et al. (2004). Dopamine D1 and D2 receptor Co-Activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279: 35671-35678
69. Lewis DA (2012). Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions. Eur J Neurosci 35: 1871-1878
70. Lidow MS (2003). Calcium signaling dysfunction in schizophrenia: A unifying approach. Brain Res Brain Res Rev 43: 70-84
71. Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH et al. (2006). Modulation of D2RNR2B interactions in response to cocaine. Neuron 52: 897-909
72. López-Gimé nez JF, Canals M, Pediani JD, Milligan G (2007). The alpha1badrenoceptor exists as a higher-order oligomer: Effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol 71: 1015-1029
73. Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ (2009). Heterodimerization of dopamine receptors: New insights into functional and therapeutic significance. Parkinsonism Relat Disord (Suppl 4): S2-S7
74. Maggio R, Millan MJ (2010). Dopamine D2-D3 receptor heteromers: Pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10: 100-107
75. Mancia F, Assur Z, Herman AG, Siegel R, Hendrickson WA (2008). Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Rep 9: 363-369
76. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I et al. (2008a). Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54: 815-823
77. Marcellino D, Ferré S, Casadó V, Corté s A, Le Foll B, Mazzola C et al. (2008b). Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283: 26016-26025
78. Marcellino D, Navarro G, Sahlholm K, Nilsson J, Agnati LF, Canela EI et al. (2010). Cocaine produces D2R-mediated conformational changes in the adenosine A(2A)R-dopamine D2R heteromer. Biochem Biophys Res Commun 394: 988-992
79. Milligan G (2004). G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 66: 1-7
80. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998). Dopamine receptors: From structure to function. Physiol Rev 78: 189-225
81. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436
82. Moreno E, Hoffmann H, Gonzalez-Sepú lveda M, Navarro G, Casadó V, Cortés A et al. (2011). Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem 286: 5846-5854
83. Morphy R, Rankovic Z (2006). The physicochemical challenges of designing multiple ligands. J Med Chem 49: 4961-4970
84. Nai Q, Li S, Wang SH, Liu J, Lee FJ, Frankland PW et al. (2010). Uncoupling the D1-N-methyl-D-Aspartate (NMDA) receptor complex promotes NMDA-dependent long-Term potentiation and working memory. Biol Psychiatry 67: 246-254
85. Ng J, Rashid AJ, So CH, O'Dowd BF, George SR (2010). Activation of calcium/ calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. Neuroscience 165: 535-541
86. Novi F, Millan MJ, Corsini GU, Maggio R (2007). Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-Transfection of D(3) receptors: Potential role of heterodimer formation. J Neurochem 102: 1410-1424
87. O'Dowd BF, Ji X, Alijaniaram M, Nguyen T, George SR (2011). Separation and reformation of cell surface dopamine receptor oligomers visualized in cells. Eur J Pharmacol 658: 74-83
88. O'Dowd BF, Ji X, Nguyen T, George SR (2012). Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. Biochem Biophys Res Commun 417: 23-28
89. O'Dowd BF, Nguyen T, Ji X, George SR (2013). D(5) dopamine receptor carboxyl tail involved in D(5)-D(2) heteromer formation. Biochem Biophys Res Commun 431: 586-589
90. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24: 1149-1158
91. Pei L, Li S, Wang M, Diwan M, Anisman H, Fletcher PJ et al. (2010). Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 16: 1393-1395
92. Perreault ML, Fan T, Alijaniaram M, O'Dowd BF, George SR (2012). Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: Regulation of BDNF, GAD67 and VGLUT1/2. PLoS One 7: E33348
93. Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ et al. (2010). The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: Increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 285: 36625-36634
94. Perreault ML, Hasbi A, O'Dowd BF, George SR (2011). The dopamine D1-D2 receptor heteromer in striatal medium spiny neurons: Evidence for a third distinct neuronal pathway in basal ganglia. Front Neuroanat 5: 31
95. Perreault ML, Jones-Tabah J, O'Dowd BF, George SR (2013). A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. Int J Neuropsychopharmacol 25: 1-7
96. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA et al. (2007). International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59: 5-13
97. Porcelli S, Drago A, Fabbri C, Serretti A (2011). Mechanisms of antidepressant action: An integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry 35: 1532-1543
98. Pou C, Mannoury la Cour C, Stoddart LA, Millan MJ, Milligan G (2012). Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface. J Biol Chem 287: 8864-8878
99. Rashid AJ, O'Dowd BF, Verma V, George SR (2007b). Neuronal Gq/11-coupled dopamine receptors: An uncharted role for dopamine. Trends Pharmacol Sci 28: 551-555
100. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R et al. (2007a). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104: 654-659
101. Ridray S, Griffon N, Mignon V, Souil E, Carboni S, Diaz J et al. (1998). Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions. Eur J Neurosci 10: 1676-1686
102. Rimondini R, Ferré S, Ogren SO, Fuxe K (1997). Adenosine A2A agonists: A potential new type of atypical antipsychotic. Neuropsychopharmacology 17: 82-91
103. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000). Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157
104. Rondou P, Haegeman G, Van Craenenbroeck K (2010). The dopamine D4 receptor: Biochemical and signalling properties. Cell Mol Life Sci 67: 1971-1986
105. Salahpour A, Angers S, Mercier JF, Lagacé M, Marullo S, Bouvier M (2004). Homodimerization of the beta2-Adrenergic receptor as a prerequisite for cell surface targeting. J Biol Chem 279: 33390-33397
106. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A et al. (2001). D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276: 30308-30314
107. Scott L, Zelenin S, Malmersjo S, Kowalewski JM, Markus EZ, Nairn AC et al. (2006). Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines. Proc Natl Acad Sci USA 103: 762-767
108. Seeman P (2009). Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci 34: 143-149
109. Shen HY, Singer P, Lytle N, Wei CJ, Lan JQ, Williams-Karnesky RL et al. (2012). Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest 122: 2567-2577
110. Smith NJ, Milligan G (2010). Allostery at G protein-coupled receptor homoand heteromers: Uncharted pharmacological landscapes. Pharmacol Rev 62: 701-725
111. So CH, Varghese G, Curley KJ, Kong MM, Alijaniaram M, Ji X et al. (2005). D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 68: 568-578
112. So CH, Verma V, Alijaniaram M, Cheng R, Rashid AJ, O'Dowd BF et al. (2009). Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 75: 843-854
113. Soriano A, Ventura R, Molero A, Hoen R, Casadó V, Cortés A et al. (2009). Adenosine A2A receptor-Antagonist/dopamine D2 receptor-Agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J Med Chem 52: 5590-5602
114. Terrillon S, Bouvier M (2004). Roles of G-protein-coupled receptor dimerization. EMBO Rep 5: 30-34
115. Toda S, Alguacil LF, Kalivas PW (2003). Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J Neurochem 87: 1478-1484
116. Torvinen M, Marcellino D, Canals M, Agnati LF, Lluís C, Franco R et al. (2005). Adenosine A2A receptor and dopamine D3 receptor interactions: Evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67: 400-407
117. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614
118. Verma V, Hasbi A, O'Dowd BF, George SR (2010). Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: Dual functional regulation by G protein-coupled receptor kinase 2. J Biol Chem 285: 35092-35103
119. Vohora D, Bhowmik M (2012). Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: Relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci 6: 72
120. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004). Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569
121. Wager-Miller J, Westenbroek R, Mackie K (2002). Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121: 83-89
122. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH et al. (1998). Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396: 679-682
123. Woods AS, Ciruela F, Fuxe K, Agnati LF, Lluís C, Franco R et al. (2005). Role of electrostatic interaction in receptor-receptor heteromerization. J Mol Neurosci 26: 125-132
124. Woods AS, Ferré S (2005). Amazing stability of the arginine-phosphate electrostatic interaction. J Proteome Res 4: 1397-1402
125. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071
126. Zhang S, Yekkirala A, Tang Y, Portoghese PS. (2009). A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett 19: 6978-6980
127. Zhang ZW, Burke MW, Calakos N, Beaulieu JM, Vaucher E (2010). Confocal analysis of cholinergic and dopaminergic inputs onto pyramidal cells in the prefrontal cortex of rodents. Front Neuroanat 4: 21
128. Łukasiewicz S, Faron-Gó recka A, Dobrucki J, Polit A, Dziedzicka-Wasylewska M (2009). Studies on the role of the receptor protein motifs possibly involved in electrostatic interactions on the dopamine D1 and D2 receptor oligomerization. FEBS J 276: 760-775
129. Łukasiewicz S, Polit A, Kȩdracka-Krok S, Wȩdzony K, Mać kowiak M, Dziedzicka-Wasylewska M (2010). Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim Biophys Acta 1803: 1347-1358